AbbVie Inc. (ABBV)

Pharmaceutical Preparations

Latest Price

$255.00

TTM P/E

70.88

Normalized P/E

61.02

Div Yield

2.72%

Book Value

0.80

P/B Ratio

317.48

Valuation metrics

Norm. op. income: $13.0B (median of 7yr)

Tax rate: 12%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$29.53

88% downside

Base FCF: $22.0B (median of recent 5yr)

Growth: 5%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$178.07

30% downside

EPS: $2.36

Target P/E: 61×

Formula: EPS × P/E

P/E Fair Value

$143.96

44% downside

76.3% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	149.49M	$37.62B	8.45%	-1.26M	2026-06-30
VANGUARD CAPITAL MANAGEMENT LLC	115.40M	$29.04B	6.52%	+515.8K	2026-06-30
STATE STREET CORP	82.60M	$20.78B	4.67%	+1.38M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT LLC	48.48M	$12.20B	2.74%	-1.05M	2026-06-30
JPMORGAN CHASE & CO	47.86M	$12.17B	2.71%	-4.53M	2026-06-30
GEODE CAPITAL MANAGEMENT, LLC	47.00M	$11.80B	2.66%	+260.9K	2026-06-30
MORGAN STANLEY	38.90M	$9.79B	2.20%	+884.2K	2026-06-30
Capital Research Global Investors	30.10M	$7.57B	1.70%	-1.15M	2026-06-30
NORGES BANK	25.55M	$6.43B	1.44%	-114.2K	2026-06-30
BANK OF AMERICA CORP /DE/	21.24M	$5.34B	1.20%	-2.70M	2026-06-30